Evidence mapPaperPMID 39777935Full record

ArticlePharmacoepidemiology and drug safety2025

More Drugs and Fewer Strokes? Time Trends in CVD Medication and Incidence of Stroke With German Health Insurance Data.

Lieselotte Mond, Siegfried Geyer, Juliane Tetzlaff, Karin Weißenborn, Johanna Schneider, Jelena Epping

Abstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lieselotte MondMedical Sociology Unit, Hannover Medical School, Hanover, Germany.ORCID 0009-0009-8248-2050
Siegfried GeyerMedical Sociology Unit, Hannover Medical School, Hanover, Germany.
Juliane TetzlaffMedical Sociology Unit, Hannover Medical School, Hanover, Germany.
Karin WeißenbornDepartment of Neurology, Hannover Medical School, Hanover, Germany.
Johanna SchneiderMedical Sociology Unit, Hannover Medical School, Hanover, Germany.
Jelena EppingMedical Sociology Unit, Hannover Medical School, Hanover, Germany.

Funding

Allgemeine Ortskrankenkasse NiedersachsenDeutsche Forschungsgemeinschaft GE 1167/15-1Deutsche Forschungsgemeinschaft GE 1167/19-1
6 · The paper itself

Abstract

backgroundSuccessful prevention of cardiovascular diseases (CVD) may reduce the burden of diseases. Preventive medication is an important measure to decrease the risks of cardiovascular events, in particular myocardial infarction and stroke. The aim of this study is to analyze the prevalence of CVD preventive medication in Germany over time with respect to sex and age and to compare it with the temporal development of strokes.

methodsThe study is based on statutory health insurance claims data from the AOK Niedersachsen (AOKN) covering the years 2005-2018. The study population comprises all AOKN insured persons aged 18 years and older (N = 2 088 495). Age-standardized time trends of the prevalence of CVD preventive medication and incidence of stroke were calculated for men and women in different age groups. After that, the relationship of both measures was examined in an ecological correlation.

resultsWe found a clear increase in medication prevalence over time. In 2018, about 35% of the total population and about 85% of those over 85 years of age received CVD preventive medication. At the same time, age-standardized incidence rates of ischemic stroke were decreasing slightly. The ecological correlation showed a negative association between medication prevalence and stroke incidence especially in the higher age groups.

conclusionHigh correlation coefficients indicate that higher medication prevalence could be linked to better population health. Further research is needed to draw conclusions about the effects of increasing medicalization, including adverse risks and side effects at the population level.

Indexed as

Cardiovascular DiseasesInsurance, HealthStrokeAdolescentAdultAgedAged, 80 and overAge FactorsCardiovascular AgentsDatabases, FactualFemaleGermanyHumansIncidenceMaleMiddle AgedCardiovascular Agentsdrugsecological correlationpreventive medicationroutine datastroke

Identifiers

PMID39777935
PMCPMC11706669

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.